Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To compare the clinical outcomes of ‘on-label’ and ‘off-label’ drug-eluting stents (DESs) over a 5-year follow-up period. Methods: A total of 929 patients that underwent percutaneous coronary intervention with DESs were enrolled. Patients were divided into two groups according to on-label (n = 449) and off-label (n = 480) indications. Off-label use was defined as implantation of DESs for acute myocardial infarction (MI), very small vessel, a long stenotic lesion, chronic total occlusion, a bifurcation lesion, an ostial lesion, left main coronary artery disease, multivessel disease, a saphenous vein graft lesion, and a lesion with thrombus. Endpoints were composite of major adverse cardiac events (MACEs), which included all-cause death, ischemic-driven target vessel revascularization (Id-TVR), MI, and stent thrombosis (ST). Clinical outcomes in the two groups were compared for up to 5 years postimplantation. Results: At 1 year postimplantation, the off-label group had higher incidences of total MACEs (8.2% vs. 3.7%, p = 0.005), Id-TVR (5.0% vs. 1.6%, p = 0.004), and ST (1.7% vs. 0.3%, p = 0.042), and at 5 years postimplantation, the off-label group continued to have higher incidences of total MACEs (17.5% vs. 9.4%, p < 0.001), Id- TVR (13.1% vs. 5.8%, p = 0.024), and ST (2.1% vs. 0.3%, p = 0.021). Multivessel disease and diabetes were found to be independent risk factors of MACE in patients with an off-label indication. Conclusions: Patients treated with an on-label DES had better long-term clinical outcomes than those treated with an off-label DES.
Abstract
Background/Aims: To compare the clinical outcomes of ‘on-label’ and ‘off-label’ drug-eluting stents (DESs) over a 5-year follow-up period. Methods: A total of 929 patients that underwent percutaneous coronary intervention with DESs were enrolled. Patients were divided into two groups according to on-label (n = 449) and off-label (n = 480) indications. Off-label use was defined as implantation of DESs for acute myocardial infarction (MI), very small vessel, a long stenotic lesion, chronic total occlusion, a bifurcation lesion, an ostial lesion, left main coronary artery disease, multivessel disease, a saphenous vein graft lesion, and a lesion with thrombus. Endpoints were composite of major adverse cardiac events (MACEs), which included all-cause death, ischemic-driven target vessel revascularization (Id-TVR), MI, and stent thrombosis (ST). Clinical outcomes in the two groups were compared for up to 5 years postimplantation. Results: At 1 year postimplantation, the off-label group had higher incidences of total MACEs (8.2% vs. 3.7%, p = 0.005), Id-TVR (5.0% vs. 1.6%, p = 0.004), and ST (1.7% vs. 0.3%, p = 0.042), and at 5 years postimplantation, the off-label group continued to have higher incidences of total MACEs (17.5% vs. 9.4%, p < 0.001), Id- TVR (13.1% vs. 5.8%, p = 0.024), and ST (2.1% vs. 0.3%, p = 0.021). Multivessel disease and diabetes were found to be independent risk factors of MACE in patients with an off-label indication. Conclusions: Patients treated with an on-label DES had better long-term clinical outcomes than those treated with an off-label DES.
참고문헌 (20)
- Spaulding C, "A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents", N Engl J Med, 356, pp.989~997 (2007)
- Moses JW, "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery", N Engl J Med, 349, pp.1315~1323 (2003)
- Stone GW, "Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents", N Engl J Med, 356, pp.998~1008 (2007)
- Kimura T, "Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry", Circulation, 125, pp.584~591 (2012)
- Roy P, "Impact of"off-label"utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention", Am J Cardiol, 101, pp.293~299 (2008)
- Qasim A, "Long-term follow-up of drug-eluting stents when inserted for on-and off-label indications", Am J Cardiol, 100, pp.1619~1624 (2007)
- Poorhosseini H, "On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes", Tex Heart Inst J, 39, pp.24~29 (2012)
- Win HK, "Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents", JAMA, 297, pp.2001~2009 (2007)
- Brodie BR, "Outcomes and complications with off-label use of drug-eluting stents:results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group", JACC Cardiovasc Interv, 1, pp.405~414 (2008)
- Windecker S, "Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization", N Engl J Med, 353, pp.653~662 (2005)
- Stone GW, "A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease", N Engl J Med, 350, pp.221~231 (2004)
- "Resolute integrity zotarolimus coronary stent system" (2015)[URL]
- Levine GN, "ACCF", AHA, American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, pp.Circulation, 2011[DOI]
- Singh M, "Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial", J Am Coll Cardiol, 45, pp.198~203 (2005)
- Cutlip DE, "Clinical end points in coronary stent trials: a case for standardized definitions", Circulation, 115, pp.2344~2351 (2007)
- Kotani J, "Long-term outcomes following off-label use of sirolimus-eluting stent", J Cardiol, 62, pp.151~157 (2013)
- Bauer T, "Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES. DE-Registry", Clin Res Cardiol, 100, pp.701~709 (2011)
- Galasso G, "Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: a prospective registry", J Invasive Cardiol, 24, pp.251~255 (2012)
- Serruys PW, "Comparison of zotarolimus-eluting and everolimus-eluting coronary stents", N Engl J Med, 363, pp.136~146 (2010)
- Gilbert J, "Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting", Diabetes Care, 27, pp.990~994 (2004)